Eli Lilly and Company has announced a strategic agreement with Indian pharmaceutical company Cipla to enhance the reach of its blockbuster drug, tirzepatide, in India. Under the terms of the partnership, Cipla will distribute and promote the drug under the brand name Yurpeak®, which will be a second brand for tirzepatide in the country, alongside Mounjaro®. Lilly will be responsible for the manufacturing and supply of Yurpeak® to Cipla, ensuring that the pricing remains consistent with that of Mounjaro®. This collaboration is aimed at leveraging Cipla's extensive distribution network to make tirzepatide, a treatment for type 2 diabetes and obesity, more accessible to patients across India, especially in areas beyond Lilly's current reach. The move is part of Lilly's broader strategy to increase global access to its innovative therapies and addresses the growing health concerns of diabetes and obesity in India. Financial terms of the agreement were not disclosed, and there has been no significant market reaction analysis reported so far.